Clinical Trials | April 16, 2024
Novartis reports data from trial of IgA nephropathy treatment
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
WINREVAIR is a breakthrough biologic for this rare, progressive disease
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
Elegen is the only DNA manufacturer delivering the unique combination of complexity, length and NGS-verified accuracy within days
Subscribe To Our Newsletter & Stay Updated
